Zenobia Therapeutics specializes in fragment-based lead discovery (FBLD) to develop treatments for neurodegenerative diseases. The company has established a comprehensive fragment library consisting of 967 diverse fragments that adhere to their internal guidelines, which are utilized in their internal central nervous system (CNS) discovery research programs. These fragments have proven effective in yielding hits for a variety of targets globally, showcasing the company's commitment to advancing drug discovery through innovative methodologies.

In addition to their fragment library, Zenobia Therapeutics offers unique reagents known as "fradditives" that facilitate protein solubilization and crystallization, essential processes in structural biology. The company also provides screening and structural biology services to complement their fragment library, enhancing the overall utility of their products for researchers in the field. This integrated approach underscores Zenobia's dedication to supporting the scientific community in the pursuit of effective therapies for CNS diseases.

Zenobia Therapeutics

Company Details